ASTRAZEN

AstraZeneca Pharma India Limited

Source: NSE · Updated 5 Nov, 10:00 pm IST

Filed 5 Nov, 05:42 pm IST Q2 FY27 (Sep ’26)Standalone (no consolidated filing)₹ millions

Revenue

7,291

▲ 30.4% vs Q2 FY26

Operating profit (EBITDA, derived from filing)

955.7

▲ 27.1% vs Q2 FY26

Net profit

623.3

▲ 15.0% vs Q2 FY26

EPS (₹)

24.93

▲ 14.9% vs Q2 FY26

Operating margin

13.1%

−30 bps vs Q2 FY26

Net margin

8.5%

−120 bps vs Q2 FY26

Revenue up, profit up vs Q2 FY26

Revenue+30% vs Q2 FY26 · +7% vs Q1 FY27

Profit+15% vs Q2 FY26 · +64% vs Q1 FY27

View official filing ↗

Numbers from the company's structured XBRL filing on NSE, cross-checked with P&L totals and the filing PDF.

Quarter comparison

Item	Q2 FY27 (Sep ’26)	Q1 FY27 (Jun ’26)	vs Q1 FY27	Q2 FY26 (Sep ’25)	vs Q2 FY26
Revenue from operations	7,291	6,827.9	▲ 6.8%	5,590.9	▲ 30.4%
Other income	151.2	92.3	▲ 63.8%	61.7	▲ 145.1%
Total income	7,442.2	6,920.2	▲ 7.5%	5,652.6	▲ 31.7%
Total expenses	6,407.7	6,410.3	▼ 0.0%	4,871.5	▲ 31.5%
Operating profit (EBITDA)*	955.7	489.4	▲ 95.3%	751.8	▲ 27.1%
Tax expense	261.6	128.2	▲ 104.1%	186	▲ 40.6%
Net profit	623.3	379.3	▲ 64.3%	542.2	▲ 15.0%
EPS (₹)	24.93	15.17	▲ 64.3%	21.69	▲ 14.9%
Operating margin	13.1%	7.2%	+590 bps	13.4%	−30 bps
Net margin	8.5%	5.6%	+290 bps	9.7%	−120 bps

Showing Q2 FY27 (Sep ’26) and change vs Q2 FY26. Turn your phone sideways for Q1 FY27 (Jun ’26).

Figures in ₹ millions except EPS. Standalone figures from the company's XBRL filing on NSE. Each row is shown only if it reconciles with the others (e.g. PBT − tax = net profit); rows we couldn't verify are left out. Net margin = net profit ÷ revenue. *Operating profit (EBITDA), derived from the filing: profit before exceptional items and tax + finance costs + depreciation − other income. Operating margin = EBITDA ÷ revenue.

All AstraZeneca Pharma India results, dividends & filings ›

Other results filed 5 Nov

NIMBSPROJ Nimbus Projects Limited›IKS Inventurus Knowledge Solutions Limited›ASHOKA Ashoka Buildcon Limited›POWERICA Powerica Limited›DBREALTY Valor Estate Limited›GOKEX Gokaldas Exports Limited›LEMONTREE Lemon Tree Hotels Limited›TIMETECHNO Time Technoplast Limited›BAGFILMS B.A.G Films and Media Limited›MUTHOOTCAP Muthoot Capital Services Limited›ARMEE ArMee Infotech Limited›MMFL MM Forgings Limited›

Today's results ›

ASTRAZENECA PHARMA INDIA Q2 FY27 ; NET PROFIT UP 15% AT ₹62 CR (YOY), UP 64% (QOQ)

REVENUE UP 30% AT ₹729 CR (YOY), UP 7% (QOQ)

EBITDA UP 27% AT ₹96 CR (YOY), UP 95% (QOQ)

MARGINS AT 13.1% VS 13.4% (YOY), 7.2% (QOQ)

https://resultkal.com/r/astrazen-2026-11-05
Source: NSE filing · not investment advice

FAQ

When did AstraZeneca Pharma India announce Q2 FY27 results?

AstraZeneca Pharma India filed its results on NSE on 5 Nov, 05:42 pm IST.

What does QoQ and YoY mean?

QoQ compares with the previous quarter; YoY compares with the same quarter last year. Growth is calculated from the figures in the filing.

Are these AstraZeneca Pharma India figures official?

They are auto-read from the company's NSE filing and may contain errors. Always confirm with the official PDF linked on this page.

Explore

Today's results Results this week Q2 FY27 results dates Dividend stocks this week Bonus issue 2026 Stock split 2026

Figures are auto-read from the company's NSE filing and may contain errors. Check the official filing before deciding. Not investment advice.

← ASTRAZEN overview